Tes Pharma Announces Appointment of Andrea Pellacani, MD, PhD, as Chief Medical Officer
Solomeo-Corciano (PG), Italy, January 28– Tes Pharma, a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in oncology, renal and metabolic diseases, today announced the appointment of Andrea Pellacani, MD, PhD, as Chief Medical Officer (CMO).
Dr Pellacani brings over 25 years of international leadership experience in the pharmaceutical industry. He has held senior medical and research & development roles in the US at Abbott, GSK, Merck, and Amgen, where he led multiple successful discovery and development projects across the entire development spectrum. He returned to Italy in 2015 to join the Menarini Group as Head of R&D, and most recently he led the R&D organization at Alfasigma.
“Tes pharma is rapidly advancing its first-in-class portfolio into the clinic,” said Luca Benatti, Chief Executive Officer of Tes pharma. “Andrea is a great addition to our team and brings significant experience in the design and execution of development programs across key therapeutic areas”.
Andrea Pellacani MD, PhD, commented as follow: “I am very excited to join Tes Pharma to advance their innovative investigational compounds into clinical development, and I look forward to working with the team and contributing to the success of the Company’s pipeline”
Dr Pellacani received his PhD in Biochemistry and MD degrees from the University of Torino, Italy, and he completed his post-doctoral training at Harvard University, where he also held a junior faculty position as Instructor in Medicine.
About Tes Pharma
Tes Pharma is a biotech company focused on delivering first-in-class therapeutics for high unmet medical needs in metabolic, renal diseases and oncology. Tes Pharma’s clinically validated drug discovery engine generates rationally designed drug candidates for novel targets. Tes Pharma has a long-standing partnership with Intercept for the discovery and development of bile acid derivatives for the treatment of liver disease. INT-787 is undergoing Phase 2 clinical studies for the treatment of severe alcohol-associated hepatitis (sAH). Separate from the collaboration with Intercept, Tes Pharma is also developing TES-AKI-01 and TES-ONC-07, two first-in-class small molecules for the treatment of acute kidney injury and for cancer immunotherapy, respectively, that are entering IND-enabling studies. Also, Tes Pharma has an undisclosed pipeline of additional projects in the early phase of drug discovery.
For more information, please visit www.tespharma.com or connect with the Company on LinkedIn
For further information, please contact:
Sara Malincarne